Patrys Limited

PAB

Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. The company has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.

Pacific Current Group Limited

PAC

Pacific Current Group Ltd. engages in the business of investing in asset managers, private advisory, placement, and investment related firms. The company is headquartered in Sydney, New South Wales and currently employs 20 full-time employees. The firm is engaged in investing in asset managers, private advisory, placement and investment-related firms on a global basis. The firm operates a portfolio of 15 specialist boutiques in Australia, India, Luxembourg, the United States, and the United Kingdom. The Company’s portfolio represents an array of strategies, diversified across investment strategy, geography, revenue model, and client type. Its portfolio of companies includes Aether Investment Partners, LLC, Astarte Capital Partners, LLP, Carlisle Management Company, S.C.A., Cordillera Investment Partners, LP, Victory Park Capital Advisors, LLC and others. Aether Investment Partners, LLC is focused on private investments in natural resources, infrastructure and opportunistic real assets. Astarte Capital Partners, LLP is focused on infrastructure, natural resources, transportation, and real estate.

Pharmaust Limited

PAA

PharmAust Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-10-05. The Company’s segments include Corporate and Research. The firm is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The firm's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The firm is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. The company is focused on starting Phase II/III clinical study of MPL. The company has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. The company is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.